A 100-member angel network based in the USA has invested over $60 million in almost 200 deals.  The group considers early stage companies in a wide range of industry sectors including life sciences. The group can either lead or co-invest in a financing round from $25K to up to $500K per deal. Investments are made in convertible preferred equity or convertible notes depending on the deal. The group is seeking new opportunities across the US.

Within life sciences, the angel network is most interested in early stage medical device, diagnostic, and healthcare IT innovations. The group considers medical devices at all risk levels and is agnostic to disease indications. The group would also consider therapeutics, but with less interest as the development timeline and risks of early stage therapeutics are often not suitable for the group.

The angel network is looking for competent entrepreneurs with sector expertise. The group seeks active participation after investment and can help build the management team when needed. The group typically avoids crowdfunded investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-based healthcare-specific RMB fund has raised three funds to date and is now investing from its recently closed third fund. The firm is actively seeking to invest in early-growth and revenue-stage China-based companies, and also considers offshore companies that have significant operations in China or products that are strongly applicable to the Chinese market.

The firm is currently seeking companies in the healthcare service sector, which includes healthcare record management systems, healthcare IT, and mobile health. The firm is also interested in innovative medical devices that have large market potential. The firm is agnostic to therapeutic indications, but is not interested in large hospital equipment. The firm looks for companies that have “disruptive” technologies and/or products or business models that are game-changing. The firm prefers early-growth and revenue-stage companies, while it also invest in select early ventures that seek to establish critical infrastructures and platforms in the evolving Chinese healthcare industry.

The firm invests in entrepreneurs who have unique insights, exceptional domain knowledge and deep operational experience. In particular, the firm looks for management teams with successful track records in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate VC arm of a large pharmaceutical company manages an evergreen fund with $400 million in assets under management. The firm looks to make investments generally in seed and Series A rounds with up to $10 million initially and up to $25 over the lifetime of the investment. The firm is open to reviewing opportunities from all around the globe.

The firm is currently interested in companies operating in sectors of therapeutics, diagnostics, medical devices and healthcare IT. The firm is fairly open to all types of technologies within these sectors pending that it be truly novel. The firm is not interested in pure reformulations or repurposing plays, and a higher level of interested in the cell and gene therapy spaces. For therapeutics the firm generally looks for companies in either pre-clinical or phase I of clinical development and for devices and diagnostics the firm will generally considers those that are in the clinical or already on the market. Only in cases of drug delivery devices would the firm look early than the clinical stage for devices. The firm is also open to technologies in all indication areas but generally only consider technologies targeting crowded spaces such as diabetes and Alzheimer’s if they are truly disruptive.

The firm is looking for privately held companies with experienced management teams and always look to take a board seat following investment. From time to time members of the firm have acted as management within portfolio companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fully integrated healthcare solution provider that was founded in 1993 and is headquartered in China is seeking in-licensing, acquisition, and partnership opportunities. For early stage assets, allocation sizes can be flexible, ranging from $2-10M per deal. The firm can either lead or co-invest in a financing round. The firm prefers companies with a China angle and seeks distribution rights in the Chinese market; however this is not a prerequisite criterion. The firm is currently looking for opportunities throughout North America and China.

The firm considers a wide range of technology sectors including therapeutics, medical devices, diagnostics, and healthcare IT. In therapeutics, the firm is interested in small molecules, biologics, cell and gene therapies, and biosimilars for oncology, women’s health, CNS, pain management, and infectious diseases. The firm seeks assets from preclinical stage to proof-of-concept phase 1. In medical devices, the firm prefers 510K and low-risk devices.

The firm is looking for companies with a complete management team formed by devoted and trustworthy members with domain expertise. The firm typically seeks board representation after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international investment group based in California looks to make equity investments into early stage companies in the life science and technology sectors. The firm makes investments generally ranging from $50,000 to $500,000 into companies and is generally involved in 2-4 deals per year. The firm is willing to consider companies around the globe.

The firm is generally open to all areas within the life sciences though they tend to avoid drug development opportunities as the capital requirements are too large. The firm has current interest in companies in the bioinformatics spaces utilizing genomics and/or proteomics that aid in the drug discovery process, as well as other implementations of bioinformatics. The firm is also open to medical devices across technology types and indication areas. The firm generally makes investment in the seed and series A stages.

The firm is looking for privately held companies with motivated management teams. The firm looks to take board seats into companies on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large biotech firm utilizes an evergreen structure and currently holds $750 million in assets under management. The fund invests separately from its parent and is not mandated to invest in areas of strategic relevance with it parent. The firm makes equity investments in early venture rounds. The firm typically invests up to $10 million initially with a total of $15-25 million going to a single company over multiple financing rounds. The firm is willing to both lead and co-invest in companies located around the globe and could make as many as 5-6 investments over the next year.

The firm invests in therapeutics, medical devices, diagnostics, and healthcare IT. The firm invests in early stages of development, from preclinical through to Phase IIa drug trials for therapeutics; and for medical devices and diagnostics, the firm prefers to invest in companies that are anywhere from in-development to on the market.  The firm is interested in all classes and indications of therapeutics, devices, and diagnostics with their main focus being that the technology be truly innovative and novel. They are not interested in cases of reformulations, repurposing or “me too” ideas. The firm makes approximately 75% of its investment in therapeutics and 25% across medical devices, diagnostics and healthcare IT although they are actively looking to increase exposure in these areas. The firm is also open to investing in laboratory equipment and drug development enabling technologies though this area is less of a focus.

The firm prefers to invest in management teams that have demonstrated prior success in the life science industry and are oriented on the goal of bringing a product to market. The firm is currently most interested in privately held companies and looks to take a board seat following investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the southern United States is currently making investments out of its vintage 2013. The fund currently has approximately $200 under management. The firm is looking to make equity investments in companies ranging from $500,000 to $3million. The firm will invest in companies across the United States and plans to make approximately 3-4 investments over the next 6-9 months.

The firm is currently most interested in areas of personalized medicine diagnostics, particularly in the genomic and proteomic subsectors. Other areas of high interest include: digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit. The firm is looking to invest in early to mid-stage companies and generally does not make seed investments.

The firm invests in privately help companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com